The Impact of a 48-hour Fast with or Without Exercise on Immune Cell Metabolism and Glycemic Cont… (NCT06737224) | Clinical Trial Compass
RecruitingNot Applicable
The Impact of a 48-hour Fast with or Without Exercise on Immune Cell Metabolism and Glycemic Control in Healthy Active Adults
Canada15 participantsStarted 2025-01-10
Plain-language summary
Many individuals engage in fasting for its purported health benefits but the effects of fasting on immune cell and whole body metabolism are not well understood in humans. Moreover, how exercising during a prolonged fast impacts immunometabolic outcomes is unclear. This study will determine how a 2 day fast - performed with or without daily exercise - impacts immune cell bioenergetics, immune cell function, and whole-body glycemic control in healthy active individuals.
Who can participate
Age range
19 Years – 35 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged between 19 and 35 years.
* Physically active (engaging in ≥150 minutes of weekly moderate to vigorous physical activity).
Exclusion Criteria:
* History of cardiometabolic diseases or inflammatory diseases (e.g., chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, cardiovascular disease).
* Individuals currently following a ketogenic diet, low-calorie diet, periodic fasting regimen, or consuming ketogenic supplements (e.g., exogenous ketone drinks).
* Cigarette/vaping smoking.
* Physical limitation that will impair the ability of the participant to perform exercise.
* Individuals having a body mass index (BMI) over 30 kg/m2.
* Cancer diagnosis in the past 5 years.
* Taking anti-inflammatory drugs (e.g., ibuprofen, aspirin, naproxen).
* Being unable to read or communicate in English.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Monocyte mitochondrial respiration
Timeframe: Baseline and 48 hours
Trial details
NCT IDNCT06737224
SponsorUniversity of British Columbia
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2025-08-01
Contact for this trial
Jonathan Little Principal Investigator, Professor Little, Ph.D